Interspecies embryo transfer and gestation
Carrying an embryo of one species to term in a surrogate of a different species, the only route to a live animal when no conspecific female exists.
State of the art
Edited gray-wolf-derived embryos gestated in domestic dog surrogates gave two live births from 45 embryos (2025); BioRescue transferred pure northern white rhino embryos into southern white rhino surrogates in July 2024, December 2024 and May 2025 with no lasting pregnancy.
- Placental and immunological incompatibility between embryo and surrogate species causes early loss
- Success rates of a few percent mean each live birth consumes many embryos and surrogate cycles
- Oocyte supply for enucleation depends on the surrogate species, which constrains how distant the target species can be
- Maternal behavior, microbiome and milk of the wrong species shape the offspring after birth
Who’s working on it
- BioRescue ↗Program
German-funded consortium that had conducted six northern white rhino embryo transfers into southern white rhino surrogates as of April 2026, none yielding a lasting pregnancy
- Thomas HildebrandtResearcherLeibniz Institute for Zoo and Wildlife Research
Heads BioRescue and performs the rhino transfers; received the inaugural Smart Wildlife Conservation Award in January 2026
- Colossal Biosciences ↗Startup
Gestated edited gray-wolf embryos in domestic dog surrogates (announced 2025) and in April 2026 announced a bluebuck programme that will use roan antelope surrogates
- AvanteaCompany
Cesare Galli's Italian laboratory, which produces the northern white rhino IVF embryos and derived the first southern white rhino embryonic stem cells in 2018
- Katsuhiko HayashiResearcherOsaka University and Kyushu University
Co-led an October 2026 study generating rhino germ-cell precursors in vitro, the only route to embryos once no oocytes remain
- Sebastian DieckeResearcherMax Delbruck Center for Molecular Medicine
Leads the stem-cell arm of BioRescue, deriving iPSC lines from deceased northern white rhinos for in vitro gametogenesis
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Comparative placentation studies and immunomodulation protocols for cross-species pregnancy in two model pairs | $$ $10M – $100M |
| engineering | Non-invasive early pregnancy monitoring and hormonal support protocols for large-mammal surrogates | $$ $10M – $100M |
Depends on
Required by
No other capability builds on this directly.